SEPN

Septerna is a clinical-stage biotech, not an operating business you can value on the numbers. Management is explicit: 'We have not had any products approved for sale and have not generated any revenue from product sales,' and revenue 'to date has been generated solely from research services.' The reported $46.0M FY2025 revenue is collaboration/research-services income, not commercial sales — lumpy and non-recurring, which is why the P/S of 33x is economically meaningless here. The company has lost money every year since inception except 2023, carries a $167.3M accumulated deficit, and states it 'expect[s] to continue to incur significant and increasing net operating losses for the next several years.' The whole equity rests on two lead programs (SEP-479, SEP-631) and a preclinical Native Complex GPCR platform whose value is entirely contingent on clinical data that does not yet exist.

The balance sheet is the one genuine strength and the reason this is 'avoid' rather than 'sell': $411M current assets against only $86.9M current liabilities, $382M equity, and liabilities/equity of just 0.56x. But read the cash lines together — cash & equivalents fell 49% to $121M even as reported operating cash flow swung to +$110M. That positive OCF is almost certainly a one-time upfront collaboration payment (total liabilities jumped +487% and current liabilities +577%, consistent with a large deferred-revenue inflow), not sustainable operating generation; the cash itself was largely rotated into investments. Underlying, R&D spend rose 49% to $97.6M against a $68.3M operating loss, so the real burn is heavy and accelerating by management's own guidance.